Please Wait.....
Report
Biologics Market Size, Share and Growth Analysis Report - Forecast Trends and Outlook (2026-2035)
Market Report I 2026-05-20 I 350 Pages I EMR Inc.
The biologics market was valued at USD 409.40 Billion in 2025 . It is poised to grow at a CAGR of 7.20% during the forecast period of 2026-2035, and reach USD 820.53 Billion by 2035 . Rising prevalence of chronic diseases, increasing demand for targeted therapies, and advancements in biotechnology are driving market growth, supported by strong pipelines, regulatory approvals, and expanding healthcare infrastructure globally.
Key Market Trends and Insights
- Based on region, North America held the largest revenue share of nearly 44% during the historical period.
- Based on the indication segment, oncology dominated the market with a share of more than 28% during the historical period.
- Based on product, the monoclonal antibodies segment accounted for a share of above 66% during the historical period.
Market Size and Forecast
- Market Size (2025): USD 409.40 Billion
- Projected Market Size (2035): USD 820.53 Billion
- CAGR (2026-2035): 7.20%
Biologics Market Overview
The biologics market is witnessing strong growth driven by rising demand for targeted therapies, increasing chronic disease prevalence, and continuous innovation in advanced therapeutics. Expanding applications in oncology and immunology are accelerating adoption globally, particularly with the growing use of monoclonal antibody treatments. Supportive regulatory frameworks and growing investment in research and development are further strengthening market expansion, while advancements in manufacturing technologies continue to enhance production efficiency and accessibility of biologic treatments. The market reached a value of approximately USD 409.40 Billion in 2025 .
Biologics Market Growth Drivers
Rising FDA Support for Biosimilar Approvals Driving the Market Value
Regulatory reforms and biologics approvals are catalyzing industry growth. For instance, in March 2026, the U.S. FDA issued new draft guidance aimed at simplifying biosimilar development by easing testing requirements and reducing costs up to 50%, potentially enabling broader market access and increased competition among high?cost biologic therapies. This initiative is expected to accelerate development timelines and expand treatment choices for patients globally.
Biologics Market Trends
Key trends shaping the biologics market include rising adoption of monoclonal antibody therapies, expanding biomanufacturing capabilities, increasing biologic approvals, and growing investment in antibody-drug conjugates globally.
Rising Strategic Partnerships Boosting the Market Expansion
Strategic collaborations are strengthening biologics pipelines worldwide and strengthening the market. For instance, in February 2026, Eli Lilly and Innovent Biologics entered a USD 8.8 billion agreement to co-develop multiple monoclonal antibody therapies across oncology and immunology. The partnership extends beyond traditional licensing, focusing on early-stage research, clinical development, and commercialization of antibody-based biologics. This move is expected to strengthen Lilly's global biologics pipeline, enhance cross-border R&D capabilities, and drive next-generation therapeutic advancements.
Biologics Market Segmentation
Market Breakup by Source
- Microbial
- Mammalian
Market Breakup by Product
- Monoclonal Antibodies
??- Human mABs
??- Humanized mABs
??- Chimeric mABs
??- Murine mABs
- Vaccines
- Recombinant Proteins
- Antisense, RNAi & molecular therapy
- Cell Based Therapies
??- Stem Cell Therapy
??- CAR-T Cell Therapy
- Tissue Engineering
- Others
Market Breakup by Indication
- Oncology
- Immunological Disorders
- Cardiovascular Disorders
- Hematological Disorders
- Others
Market Breakup by Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Market Breakup by Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
Biologics Market Share
Oncology Expected to Dominate the Market Segment by Indication
Based on the indication segment, oncology dominated the market with a share of more than 28% during the historical period. This leadership is driven by increasing adoption of targeted therapies, particularly monoclonal antibody treatments, across various cancer types. Rising cancer prevalence, strong clinical efficacy, and continuous innovation in biologic therapies have further strengthened demand, supporting sustained growth of the oncology segment within the global biologics market.
Biologics Market Analysis by Region
North America held the largest revenue share of nearly 44% in the historical period. This dominance is supported by advanced healthcare infrastructure, strong regulatory frameworks, and high investment in biomanufacturing capabilities. The presence of leading biologics manufacturers, increasing biologic approvals, and growing adoption of advanced therapies are further driving regional growth, reinforcing its leading position in the global market.
Leading Players in the Biologics Market
The key features of the market report comprise patent analysis, funding analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:
AbbVie Inc.
AbbVie Inc. is a U.S.-based biopharmaceutical company headquartered in North Chicago, Illinois, founded in 2013. It focuses on immunology, oncology, neuroscience, and aesthetics, with a strong biologics portfolio including monoclonal antibody therapies such as Humira and Skyrizi. The company emphasizes advanced biologic innovation and global commercialization. In December 2024, AbbVie acquired ImmunoGen to strengthen its oncology pipeline and expand antibody-drug conjugate capabilities.
Amgen Inc.
Amgen Inc. is a U.S.-based biotechnology company headquartered in Thousand Oaks, California, established in 1980. It specializes in oncology, cardiovascular disease, inflammation, and bone health, with a diverse biologics portfolio including biosimilar products and innovative therapies. The company is a leader in biologic drug development and commercialization. In October 2023, Amgen completed its USD 27.8 billion acquisition of Horizon Therapeutics, expanding its rare disease and biologics portfolio.
Lilly (Eli Lilly and Company)
Eli Lilly and Company is a U.S.-based pharmaceutical firm headquartered in Indianapolis, Indiana, founded in 1876. It focuses on diabetes, oncology, immunology, and neuroscience, with a growing biologics pipeline including gene therapy biologic and antibody-based treatments. The company is expanding its advanced therapeutics capabilities globally. In November 2023, Lilly acquired POINT Biopharma to enhance its oncology biologics and radiopharmaceutical portfolio.
F. Hoffmann-La Roche AG
F. Hoffmann-La Roche AG is a Switzerland-based pharmaceutical company headquartered in Basel, founded in 1896. It is a global leader in oncology, diagnostics, and immunology, with a robust portfolio including biologics such as antibody-drug conjugate therapies. Roche is known for pioneering precision medicine and targeted biologics. In October 2024, Roche announced positive Phase III results for its breast cancer biologic therapy enhancing oncology pipeline strength.
Other key players in the market are Samsung Biologics, Sanofi, Pfizer Inc., Merck & Co., Inc., Novo Nordisk A/S, Johnson & Johnson Services, Inc., Bristol-Myers Squibb Company, Celltrion Inc., BD, Bayer AG, and AstraZeneca.
Key Questions Answered in the Biologics Market
- What was the biologics market value in 2025?
- What is the biologics market forecast outlook for 2026-2035?
- What major factors aid the demand for biologics market?
- How has the market performed so far, and how is it anticipated to perform in the coming years?
- What are the market's major drivers, opportunities, and restraints?
- What are the major biologics market trends?
- Which source is expected to dominate the market segment?
- Which product is expected to dominate the market segment?
- Which indication is projected to lead the market segment?
- Which distribution channel is likely to lead the market segment?
- Who are the key players in the biologics market?
- What are the current unmet needs and challenges in the market?
- How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?
More Insights On
Spine Biologics Market
Orthobiologics Market
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage - Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Biologics Market Overview
3.1 Global Biologics Market Historical Value (2019-2025)
3.2 Global Biologics Market Forecast Value (2026-2035)
4 Global Biologics Market Landscape*
4.1 Global Biologics Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Global Biologics Product Landscape
4.2.1 Analysis by Source
4.2.2 Analysis by Product
5 Global Biologics Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.2.1 Strengths
5.2.2 Weaknesses
5.2.3 Opportunities
5.2.4 Threats
5.3 Porter's Five Forces Model
5.3.1 Bargaining Power of Suppliers
5.3.2 Bargaining Power of Buyers
5.3.3 Threat of New Entrants
5.3.4 Threat of Substitutes
5.3.5 Degree of Rivalry
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Global Biologics Market Segmentation (219-2035)
6.1 Global Biologics Market (2019-2035) by Source
6.1.1 Market Overview
6.1.2 Microbial
6.1.3 Mammalian
6.2 Global Biologics Market (2019-2035) by Product
6.2.1 Market Overview
6.2.2 Monoclonal Antibodies
6.2.2.1 Human mABs
6.2.2.2 Humanized mABs
6.2.2.3 Chimeric mABs
6.2.2.4 Murine mABs
6.2.3 Vaccines
6.2.4 Recombinant Proteins
6.2.5 Antisense, RNAi & molecular therapy
6.2.6 Cell Based Therapies
6.2.6.1 Stem Cell Therapy
6.2.6.2 CAR-T Cell Therapy
6.2.7 Tissue Engineering
6.2.8 Others
6.3 Global Biologics Market (2019-2035) by Indication
6.3.1 Market Overview
6.3.2 Oncology
6.3.3 Immunological Disorders
6.3.4 Cardiovascular Disorders
6.3.5 Hematological Disorders
6.3.6 Others
6.4 Global Biologics Market (2019-2035) by Distribution Channel
6.4.1 Hospital Pharmacies
6.4.2 Retail Pharmacies
6.4.3 Online Pharmacies
6.5 Global Biologics Market (2019-2035) by Region
6.5.1 Market Overview
6.5.2 North America
6.5.3 Europe
6.5.4 Asia Pacific
6.5.5 Latin America
6.5.6 Middle East and Africa
7 North America Biologics Market (219-2035)
7.1 North America Biologics Market (2019-2035) by Source
7.1.1 Market Overview
7.1.2 Microbial
7.1.3 Mammalian
7.2 North America Biologics Market (2019-2035) by Product
7.2.1 Market Overview
7.2.2 Monoclonal Antibodies
7.2.2.1 Human Monoclonal Antibodies
7.2.2.2 Humanized Monoclonal Antibodies
7.2.2.3 Chimeric Monoclonal Antibodies
7.2.2.4 Murine Monoclonal Antibodies
7.2.3 Vaccines
7.2.4 Recombinant Proteins
7.2.5 Antisense, RNAi & molecular therapy
7.2.6 Cell Based Therapies
7.2.6.1 Stem Cell Therapy
7.2.6.2 CAR-T Cell Therapy
7.2.7 Tissue Engineering
7.2.8 Others
7.3 North America Biologics Market (2019-2035) by Country
7.3.1 United States of America
7.3.2 Canada
8 Europe Biologics Market (219-2035)
8.1 Europe Biologics Market (2019-2035) by Source
8.1.1 Market Overview
8.1.2 Microbial
8.1.3 Mammalian
8.2 Europe Biologics Market (2019-2035) by Product
8.2.1 Market Overview
8.2.2 Monoclonal Antibodies
8.2.2.1 Human mABs
8.2.2.2 Humanized mABs
8.2.2.3 Chimeric mABs
8.2.2.4 Murine mABs
8.2.3 Vaccines
8.2.4 Recombinant Proteins
8.2.5 Antisense, RNAi & molecular therapy
8.2.6 Cell Based Therapies
8.2.6.1 Stem Cell Therapy
8.2.6.2 CAR-T Cell Therapy
8.2.7 Tissue Engineering
8.2.8 Others
8.3 Europe Biologics Market (2019-2035) by Country
8.3.1 United Kingdom
8.3.2 Germany
8.3.3 France
8.3.4 Italy
8.3.5 Others
9 Asia Pacific Biologics Market (219-2035)
9.1 Asia Pacific Biologics Market (2019-2035) by Source
9.1.1 Market Overview
9.1.2 Microbial
9.1.3 Mammalian
9.2 Asia Pacific Biologics Market (2019-2035) by Product
9.2.1 Market Overview
9.2.2 Monoclonal Antibodies
9.2.2.1 Human mABs
9.2.2.2 Humanized mABs
9.2.2.3 Chimeric mABs
9.2.2.4 Murine mABs
9.2.3 Vaccines
9.2.4 Recombinant Proteins
9.2.5 Antisense, RNAi & molecular therapy
9.2.6 Cell Based Therapies
9.2.6.1 Stem Cell Therapy
9.2.6.2 CAR-T Cell Therapy
9.2.7 Tissue Engineering
9.2.8 Others
9.3 Asia Pacific Biologics Market (2019-2035) by Country
9.3.1 China
9.3.2 Japan
9.3.3 India
9.3.4 Australia
9.3.5 ASEAN
9.3.6 Others
10 Latin America Biologics Market (219-2035)
10.1 Latin America Biologics Market (2019-2035) by Source
10.1.1 Market Overview
10.1.2 Microbial
10.1.3 Mammalian
10.2 Latin America Biologics Market (2019-2035) by Product
10.2.1 Market Overview
10.2.2 Monoclonal Antibodies
10.2.2.1 Human mABs
10.2.2.2 Humanized mABs
10.2.2.3 Chimeric mABs
10.2.2.4 Murine mABs
10.2.3 Vaccines
10.2.4 Recombinant Proteins
10.2.5 Antisense, RNAi & molecular therapy
10.2.6 Cell Based Therapies
10.2.6.1 Stem Cell Therapy
10.2.6.2 CAR-T Cell Therapy
10.2.7 Tissue Engineering
10.2.8 Others
10.3 Latin America Biologics Market (2019-2035) by Country
10.3.1 Brazil
10.3.2 Argentina
10.3.3 Mexico
10.3.4 Others
11 Middle East and Africa Biologics Market (219-2035)
11.1 Middle East and Africa Biologics Market (2019-2035) by Source
11.1.1 Market Overview
11.1.2 Microbial
11.1.3 Mammalian
11.2 Middle East and Africa Biologics Market (2019-2035) by Product
11.2.1 Market Overview
11.2.2 Monoclonal Antibodies
11.2.2.1 Human mABs
11.2.2.2 Humanized mABs
11.2.2.3 Chimeric mABs
11.2.2.4 Murine mABs
11.2.3 Vaccines
11.2.4 Recombinant Proteins
11.2.5 Antisense, RNAi & molecular therapy
11.2.6 Cell Based Therapies
11.2.6.1 Stem Cell Therapy
11.2.6.2 CAR-T Cell Therapy
11.2.7 Tissue Engineering
11.2.8 Others
11.3 Middle East and Africa Biologics Market (2019-2035) by Country
11.3.1 Saudi Arabia
11.3.2 United Arab Emirates
11.3.3 Nigeria
11.3.4 South Africa
11.3.5 Others
12 Regulatory Framework
12.1 Regulatory Overview
12.1.1 US FDA
12.1.2 EU EMA
12.1.3 INDIA CDSCO
12.1.4 JAPAN PMDA
12.1.5 Others
13 Patent Analysis
13.1 Analysis by Type of Patent
13.2 Analysis by Publication Year
13.3 Analysis by Issuing Authority
13.4 Analysis by Patent Age
13.5 Analysis by CPC Analysis
13.6 Analysis by Patent Valuation
13.7 Analysis by Key Players
14 Grants Analysis
14.1 Analysis by Year
14.2 Analysis by Amount Awarded
14.3 Analysis by Issuing Authority
14.4 Analysis by Grant Application
14.5 Analysis by Funding Institute
14.6 Analysis by NIH Departments
14.7 Analysis by Recipient Organization
15 Funding and Investment Analysis
15.1 Analysis by Funding Instances
15.2 Analysis by Type of Funding
15.3 Analysis by Funding Amount
15.4 Analysis by Leading Players
15.5 Analysis by Leading Investors
15.6 Analysis by Geography
16 Partnership and Collaborations Analysis
16.1 Analysis by Partnership Instances
16.2 Analysis by Type of Partnership
16.3 Analysis by Leading Players
16.4 Analysis by Geography
17 Supplier Landscape (Customisable)
17.1 AbbVie Inc.
17.1.1 Company Overview
17.1.2 Product Portfolio
17.1.3 Demographic Reach and Achievements
17.1.4 Mergers and Acquisitions
17.1.5 Certifications
17.2 Amgen Inc.
17.2.1 Company Overview
17.2.2 Product Portfolio
17.2.3 Demographic Reach and Achievements
17.2.4 Mergers and Acquisitions
17.2.5 Certifications
17.3 Lilly
17.3.1 Company Overview
17.3.2 Product Portfolio
17.3.3 Demographic Reach and Achievements
17.3.4 Mergers and Acquisitions
17.3.5 Certifications
17.4 F. Hoffmann-La Roche AG
17.4.1 Company Overview
17.4.2 Product Portfolio
17.4.3 Demographic Reach and Achievements
17.4.4 Mergers and Acquisitions
17.4.5 Certifications
17.5 Samsung Biologics
17.5.1 Company Overview
17.5.2 Product Portfolio
17.5.3 Demographic Reach and Achievements
17.5.4 Mergers and Acquisitions
17.5.5 Certifications
17.6 Sanofi
17.6.1 Company Overview
17.6.2 Product Portfolio
17.6.3 Demographic Reach and Achievements
17.6.4 Mergers and Acquisitions
17.6.5 Certifications
17.7 Pfizer Inc.
17.7.1 Company Overview
17.7.2 Product Portfolio
17.7.3 Demographic Reach and Achievements
17.7.4 Mergers and Acquisitions
17.7.5 Certifications
17.8 Merck & Co., Inc.
17.8.1 Company Overview
17.8.2 Product Portfolio
17.8.3 Demographic Reach and Achievements
17.8.4 Mergers and Acquisitions
17.8.5 Certifications
17.9 Novo Nordisk A/S
17.9.1 Company Overview
17.9.2 Product Portfolio
17.9.3 Demographic Reach and Achievements
17.9.4 Mergers and Acquisitions
17.9.5 Certifications
17.10 Johnson & Johnson Services, Inc.
17.10.1 Company Overview
17.10.2 Product Portfolio
17.10.3 Demographic Reach and Achievements
17.10.4 Mergers and Acquisitions
17.10.5 Certifications
17.11 Bristol-Myers Squibb Company
17.11.1 Company Overview
17.11.2 Product Portfolio
17.11.3 Demographic Reach and Achievements
17.11.4 Mergers and Acquisitions
17.11.5 Certifications
17.12 Celltrion Inc.
17.12.1 Company Overview
17.12.2 Product Portfolio
17.12.3 Demographic Reach and Achievements
17.12.4 Mergers and Acquisitions
17.12.5 Certifications
17.13 BD
17.13.1 Company Overview
17.13.2 Product Portfolio
17.13.3 Demographic Reach and Achievements
17.13.4 Mergers and Acquisitions
17.13.5 Certifications
17.14 Bayer AG
17.14.1 Company Overview
17.14.2 Product Portfolio
17.14.3 Demographic Reach and Achievements
17.14.4 Mergers and Acquisitions
17.14.5 Certifications
17.15 AstraZeneca
17.15.1 Company Overview
17.15.2 Product Portfolio
17.15.3 Demographic Reach and Achievements
17.15.4 Mergers and Acquisitions
17.15.5 Certifications
18 Global Biologics Market - Distribution Model (Additional Insight)
18.1 Overview
18.2 Potential Distributors
18.3 Key Parameters for Distribution Partner Assessment
19 Key Opinion Leaders (KOL) Insights (Additional Insight)
20 Company Competitiveness Analysis (Additional Insight)
20.1 Very Small Companies
20.2 Small Companies
20.3 Mid-Sized Companies
20.4 Large Companies
20.5 Very Large Companies
21 Payment Methods (Additional Insight)
21.1 Government Funded
21.2 Private Insurance
21.3 Out-of-Pocket
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security